For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 398,333 | |||
| General and administrative | 69,851 | |||
| Total operating expenses | 468,184 | |||
| Loss from operations | -468,184 | |||
| Interest income | 29,859 | |||
| Interest expense | 6,192 | |||
| Other expense, net | -1,697 | |||
| Total other income, net | 21,970 | |||
| Net loss | -446,214 | |||
| Unrealized gains on marketable securities, net | 469 | |||
| Comprehensive loss | -445,745 | |||
| Basic EPS | -3.47 | |||
| Diluted EPS | -3.47 | |||
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)